Skip to main content
Premium Trial:

Request an Annual Quote

Adarza BioSystems Raises $6.8M in Series A Round

NEW YORK (GenomeWeb) – Adarza BioSystems has closed the final tranche of a Series A round of financing that brought in a total of $6.8 million.

The West Henrietta, NY-based firm has developed a label-free, multiplex biosensor platform based on its Arrayed Imaging Reflectometry technology. According to the firm, the platform can rapidly identify and quantify a series of biological target analyte species in a fluid sample without the use of chemical labels.

The firm said it would use proceeds from the Series A round to launch its first 100-plex immunoassay consumable and instrument and accelerate the development of higher-plex assays for a variety of biological analytes. It didn't disclose the targets of the immunoassay product.

The firm previously received two SBIR grants from the National Institutes of Health to develop antibody arrays for detecting protein biomarkers that may indicate early cancer and for monitoring the levels of proteins linked to potentially toxic environmental exposures.

The financing round was led by Cultivation Capital Life Science Fund and the venture capital unit of Siemens.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.